Annette Westgeest

184 Chapter 8 101. Holmes, N.E.; Turnidge, J.D.; Munckhof, W.J.; Robinson, J.O.; Korman, T.; O’Sullivan, M.; Anderson, T.L.; Roberts, S.A.; Gao, W.; Christiansen, K.J.; et al. Antibiotic Choice May Not Explain Poorer Outcomes in Patients with Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations. J. Infect. Dis. 2011, 204, 340–347. 102. Neuner, E.A.; Casabar, E.; Reichley, R.; McKinnon, P.S. Clinical, microbiologic, and genetic determinants of persistent methicillin- resistant Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 2010, 67, 228–233. 103. Adani, S.; Bhowmick, T.; Weinstein, M.P.; Narayanan, N. Impact of Vancomycin MIC on Clinical Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin at an Institution with Suppressed MIC Reporting. Antimicrob. Agents Chemother. 2018, 62, e02512-17. 104. van Hal, S.J.; Paterson, D.L. Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates. Antimicrob. Agents Chemother. 2011, 55, 405–410. 105. Hiramatsu, K.; Hanaki, H.; Ino, T.; Yabuta, K.; Oguri, T.; Tenover, F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 1997, 40, 135–136. 106. Liu, C.; Chambers, H.F. Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods. Antimicrob. Agents Chemother. 2003, 47, 3040–3045. 107. Hiramatsu, K.; Kayayama, Y.; Matsuo, M.; Aiba, Y.; Saito, M.; Hishinuma, T.; Iwamoto, A. Vancomycin-intermediate resistance in Staphylococcus aureus. J. Glob. Antimicrob. Resist. 2014, 2, 213–224. 108. Howden, B.P.; Johnson, P.D.R.; Ward, P.B.; Stinear, T.P.; Davies, J.K. Isolates with Low-Level Vancomycin Resistance Associated with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob. Agents Chemother. 2006, 50, 3039–3047. 109. Gaillard, T.; Dupieux-Chabert, C.; Butin, M.; Dumitrescu, O.; Naceur, O.; Bouveyron, C.; Martra, A.; Bes, M.; Tristan, A.; Vandenesch, F.; et al. Heterogeneous vancomycin resistance in Staphylococcus aureus does not predict development of vancomycin resistance upon vancomycin pressure. J. Antimicrob. Chemother. 2022, 77, 1032–1035. 110. Casapao, A.M.; Leonard, S.N.; Davis, S.L.; Lodise, T.P.; Patel, N.; Goff, D.A.; LaPlante, K.L.; Potoski, B.A.; Rybak, M.J. Clinical Outcomes in Patients with Heterogeneous VancomycinIntermediate Staphylococcus aureus Bloodstream Infection. Antimicrob. Agents Chemother. 2013, 57, 4252–4259. 111. Hu, H.C.; Kao, K.C.; Chiu, L.C.; Chang, C.H.; Hung, C.Y.; Li, L.F.; Liu, T.P.; Lin, L.C.; Chen, N.-H.; Huang, C.C.; et al. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units. BMC Infect. Dis. 2015, 15, 444. 112. Charles, P.G.P.; Ward, P.B.; Johnson, P.D.R.; Howden, B.P.; Grayson, M.L. Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin-Intermediate Staphylococcus aureus. Clin. Infect. Dis. 2004, 38, 448–451. 113. Bae, I.; Federspiel, J.J.; Miró, J.M.; Woods, C.W.; Park, L.; Rybak, M.J.; Rude, T.H.; Bradley, S.; Bukovski, S.; de la Maria, C.G.; et al. Heterogeneous Vancomycin-Intermediate Susceptibility Phenotype in Bloodstream Methicillin-Resistant Staphylococcus aureus Isolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance. J. Infect. Dis. 2009, 200, 1355–1366.

RkJQdWJsaXNoZXIy MTk4NDMw